Articles related to ALZHEIMER'S/DEMENTIA

The landscape of Alzheimer’s treatment is evolving with the introduction of antiamyloid monoclonal antibodies. Here is some clinical guidance to stay at the forefront of patient care.

Results from the TRAILBLAZER-ALZ 2 trial highlight the efficacy of donanemab in slowing the progression of early symptomatic Alzheimer disease over a period of 76 weeks.

The emerging connection between gum disease and Alzheimer’s underlines the potential role dentists could play in early detection and prevention of this debilitating disease.

The surprising association between CHIP and a lowered risk of Alzheimer’s disease offers a novel perspective in our understanding of neurodegenerative disorders and paves the way for potential future therapeutics.

Emerging research uncovers potential associations between the use of menopausal hormone therapy and an increased risk of dementia, including Alzheimer’s disease. Discover more about the implications of these findings for women’s health management.

New findings suggest systolic blood pressure time in target range as a potential indicator for dementia risk, independent of mean SBP, underscoring the role of consistent blood pressure management in dementia prevention.